قالب وردپرس درنا توس
Home / Health / Some COVID-19 “long-distance porters” experience persistent skin problems

Some COVID-19 “long-distance porters” experience persistent skin problems



Boston-According to a new analysis, some COVID-19 patients develop persistent skin-related symptoms long after the initial infection clears. The findings presented by researchers from the Massachusetts General Hospital (MGH) at the 29th Congress of the European Society of Dermatology and Venereology pointed out that the so-called “long-distance porters” encountered another burden and their condition improved. But it seems impossible to fully recover from COVID-19.

For analysis, the researchers cooperated with the International Federation of International Dermatological Societies and the American Academy of Dermatology to establish an international registry of COVID-19 skin manifestations in April 2020. Contact the clinician in June and August to update the COVID-1

9 laboratory test results and the duration of the patient’s COVID-19 skin symptoms. The team defines a long-term porter as anyone who has skin symptoms of COVID-19 for at least 60 days.

The team evaluated nearly 1,000 patients with skin manifestations of COVID-19. Among the 224 suspected cases and 90 laboratory-confirmed COVID-19 cases in 39 countries, their symptoms lasted 12 days. For patients with laboratory-confirmed COVID-19, rash-like urine samples and urticaria lasted for 7 days and 4 days, respectively, with a maximum duration of 28 days. In laboratory-confirmed cases, squamous papules and plaque papules lasted for a median of 20 days, and one confirmed long-haired rash lasted 70 days. In patients with suspected COVID-19, redness and swelling of Pernio/calf or feet and hands (often called “COVID toes”) lasted for 15 days, compared to 10 days in laboratory confirmed cases. It is worth noting that 6 Pernio/Chibblains patients were long-distance haulers with toe symptoms lasting at least 60 days, while 2 laboratory-confirmed COVID toe patients lasted more than 130 days.

“Our findings reveal a subgroup of patients with long-term skin symptoms of COVID-19 that have never been reported before, especially those with COVID toes. These data give us an understanding of the long-term effects of COVID-19 in different organ systems. With more understanding, MGH Global Dermatology Director, Esther E. Freeman, MD, said. “We encourage clinicians caring for COVID-19 patients to ask and evaluate any skin symptoms. Healthcare providers can enter information into our registration form to learn more about the dermatological effects of COVID-19. “

###

About Massachusetts General Hospital

Founded in 1811, Massachusetts General Hospital is the original hospital of Harvard Medical School and the largest teaching hospital. The Mass General Research Institute conducts the nation’s largest hospital-based research program, with more than $1 billion in annual research operations, and more than 9,500 researchers working in more than 30 institutes, centers, and departments. In August 2020, Mass General ranked sixth in the “Best Hospitals in America” ​​list of “U.S. News and World Report.”

Disclaimer: AAAS and EurekAlert! No responsibility is assumed for the accuracy of press releases posted to EurekAlert! Use any information through donor agencies or through the EurekAlert system.


Source link